Back to Search
Start Over
On-Treatment Non–High-Density Lipoprotein Cholesterol, Apolipoprotein B, Triglycerides, and Lipid Ratios in Relation to Residual Vascular Risk After Treatment With Potent Statin Therapy JUPITER (Justification for the Use of Statins in Prevention: An Intervention Trial Evaluating Rosuvastatin)
- Source :
- Journal of the American College of Cardiology, 59(17), 1521-1528. Elsevier USA
- Publisher :
- American College of Cardiology Foundation. Published by Elsevier Inc.
-
Abstract
- Objectives The goal of this study was to determine whether residual risk after high-dose statin therapy for primary prevention individuals with reduced levels of low-density lipoprotein cholesterol (LDL-C) is related to on-treatment apolipoprotein B, non-high-density lipoprotein cholesterol (non-HDL-C), trigylcerides, or lipid ratios, and how they compare with on-treatment LDL-C. Background Guidelines focus on LDL-C as the primary target of therapy, yet residual risk for cardiovascular disease (CVD) among statin-treated individuals remains high and not fully explained. Methods Participants in the randomized placebo-controlled JUPITER (Justification for the Use of Statins in Prevention: An Intervention Trial Evaluating Rosuvastatin) trial were adults without diabetes or CVD, with baseline LDL-C levels = 2 mg/l, and triglyceride concentrations
Details
- Language :
- English
- ISSN :
- 07351097
- Issue :
- 17
- Database :
- OpenAIRE
- Journal :
- Journal of the American College of Cardiology
- Accession number :
- edsair.dedup.wf.001..f1d01afdc2721fec43cb300dd984a61a
- Full Text :
- https://doi.org/10.1016/j.jacc.2011.12.035